AbbVie reached a most‑favored‑nation (MFN) pricing agreement with the White House and publicly signaled a sweeping manufacturing investment to accompany the pact. Under terms reported at the J.P. Morgan week, AbbVie agreed to the administration’s pricing framework and pledged large capital commitments to expand U.S. biopharmaceutical production capacity. Company statements and administration materials indicate the deal includes upfront payments and multi‑year investment commitments intended to lower net patient costs while expanding domestic production of medicines. AbbVie positioned the arrangement as part of a broader industry response to federal pricing initiatives. The agreement follows similar pacts between the administration and other large pharmas and underscores how pricing negotiations are being paired with supply‑chain and manufacturing commitments to secure policy buy‑in.